NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public ...

NEW YORK, Feb. 7, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company ...

SEC Filings provided by EDGAR Online, Inc.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Kyverna To Contact Him Directly To Discuss Their Options If you... ByInvesting ...

This page features the latest news about the Kyverna Therapeutics stock. Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward autoimmune diseases in 2024. Now, CEO Nadim Ahmed wants to reset ...

Kyverna Therapeutics, Merck & Co., Novartis, RemeGen, Sanofi, Takeda California, and UCB. Other co-authors reported employment with Hoffmann-La Roche, and relationships with Genentech, BioNTech ...

In another sign that the biotech IPO market is picking up, cell therapy specialist Kyverna has filed to raise roughly $211 million from the sale of around 11 million shares at between $17 and $19 ...

Viking Holdings Ltd. provides destination-focused itineraries for curious travelers. The firm's journeys including a shore excursion in every port and an onboard and onshore enrichment program ...